Creo Medical - Solid FY21 followed by robotics deal with Intuitive
Creo Medical reported 168% y-o-y growth in its FY21 revenue (to £25.2m), broadly in line with Edison (£25.9m) and consensus estimates (£25.1m). While the increase was largely driven by the full-year contribution from Albyn Medical (acquired in July 2020), we are encouraged by the improved momentum in the core asset Speedboat Inject in H221, as COVID-19 headwinds subside. Management also announced a multi-year robotics collaboration with market leader Intuitive Surgical to optimise certain Creo products to be compatible with Intuitive’s robotic technology. The terms of the agreement include joint clinical studies and the potential for royalty and milestone payments to be received by Creo. We believe this agreement strengthens the company’s differentiated positioning in a rapidly evolving subsegment. While we wait for more details to incorporate the announcement into our valuation, we believe there may be upside potential on successful commercialisation of the covered products.Creo Medical Group is a medical device company focused on the field of surgical endoscopy, a recent development in minimally invasive surgery. Co. is focused on developing and commercializing a suite of medical devices based on its CROMA electrosurgery platform.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.